Paul Tudor Jones’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-25,916
| Closed | -$1.56M | – | 3662 |
|
|
2026
Q1 | $1.04M | Buy |
25,916
+18,848
| +267% | +$705K | ﹤0.01% | 2340 |
|
|
2025
Q4 | $246K | Buy |
+7,068
| New | +$555K | ﹤0.01% | 3168 |
|
|
2025
Q1 | – | Sell |
-53,169
| Closed | -$3.24M | – | 3154 |
|
|
2024
Q4 | $2.68M | Buy |
+53,169
| New | +$2.79M | 0.01% | 1060 |
|
|
2023
Q4 | – | Sell |
-51,242
| Closed | -$1.4M | – | 2433 |
|
|
2023
Q3 | $1.4M | Buy |
51,242
+25
| +0% | +$724 | 0.01% | 1118 |
|
|
2023
Q2 | $1.14M | Buy |
51,217
+3,338
| +7% | +$76.8K | 0.01% | 1244 |
|
|
2023
Q1 | $1.04M | Buy |
+47,879
| New | +$1.05M | 0.02% | 1174 |
|
|
2022
Q4 | – | Sell |
-34,457
| Closed | -$883K | – | 2460 |
|
|
2022
Q3 | $883K | Buy |
+34,457
| New | +$922K | 0.02% | 996 |
|
|
2020
Q3 | – | Sell |
-77,417
| Closed | -$1.3M | – | 1326 |
|
|
2020
Q2 | $1.3M | Sell |
77,417
-95,643
| -55% | -$1.34M | 0.06% | 392 |
|
|
2020
Q1 | $2.06M | Buy |
173,060
+13,606
| +9% | +$168K | 0.18% | 97 |
|
|
2019
Q4 | $1.93M | Sell |
159,454
-15,908
| -9% | -$221K | 0.09% | 294 |
|
|
2019
Q3 | $2.48M | Sell |
175,362
-61,904
| -26% | -$761K | 0.09% | 262 |
|
|
2019
Q2 | $2.65M | Buy |
237,266
+21,806
| +10% | +$243K | 0.08% | 241 |
|
|
2019
Q1 | $2.53M | Buy |
215,460
+53,058
| +33% | +$659K | 0.1% | 214 |
|
|
2018
Q4 | $2.17M | Buy |
162,402
+135,902
| +513% | +$1.8M | 0.04% | 176 |
|
|
2018
Q3 | $372K | Buy |
+26,500
| New | +$370K | 0.01% | 778 |
|
|
2018
Q2 | – | Sell |
-10,364
| Closed | -$170K | – | 1069 |
|
|
2018
Q1 | $170K | Buy |
+10,364
| New | +$192K | 0.01% | 888 |
|
|
2017
Q4 | – | Sell |
-34,734
| Closed | -$670K | – | 1101 |
|
|
2017
Q3 | $670K | Buy |
+34,734
| New | +$518K | 0.02% | 547 |
|
|
2016
Q4 | – | Sell |
-23,564
| Closed | -$153K | – | 1423 |
|
|
2016
Q3 | $153K | Sell |
23,564
-4,885
| -17% | -$28.4K | ﹤0.01% | 1298 |
|
|
2016
Q2 | $155K | Sell |
28,449
-350
| -1% | -$1.82K | ﹤0.01% | 1460 |
|
|
2016
Q1 | $135K | Buy |
28,799
+1,700
| +6% | +$6.62K | ﹤0.01% | 1578 |
|
|
2015
Q4 | $135K | Buy |
27,099
+5,820
| +27% | +$26.3K | ﹤0.01% | 1495 |
|
|
2015
Q3 | $80K | Buy |
+21,279
| New | +$108K | ﹤0.01% | 1453 |
|
Other funds holding CORT
ISL
PA
Paul Tudor Jones's CORT Position: Q2 2026 in Review
Paul Tudor Jones sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 25,916 shares — an estimated $1.56M sold.
Paul Tudor Jones first reported a position in CORT in Q3 2015 and held it in 22 quarters. The position peaked at $2.68M in Q4 2024. 420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- Paul Tudor Jones reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
- Paul Tudor Jones sold 25,916 Corcept Therapeutics shares in Q2 2026, an estimated $1.56M.
- Paul Tudor Jones first reported a position in Corcept Therapeutics in Q3 2015 and held it in 22 quarters.
- Paul Tudor Jones's Corcept Therapeutics position peaked at $2.68M in Q4 2024.
- 420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.